2024-09-10 - Analysis Report
##  REGEN Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGEN) is a biotechnology company focused on developing and commercializing life-changing medicines for serious diseases.

**1. Performance Relative to S&P 500 (VOO):**

REGEN has significantly outperformed the S&P 500, with a cumulative return of 147.14% compared to VOO's 81.34%. The current price difference is 65.8%, which represents a 92.31% position within the historical range of outperformance.  

**2. Recent Price Movement:**

* **Closing Price:** $1131.5
* **5-day Moving Average:** $1162.99
* **20-day Moving Average:** $1173.88
* **60-day Moving Average:** $1100.42

The current price is below all moving averages, indicating potential downward pressure.

**3. Technical Indicators Analysis:**

* **RSI:** 33.89 -  The RSI suggests that REGEN is currently in oversold territory.
* **PPO:** -0.83 -  A negative PPO indicates a potential downtrend.
* **Delta_Previous_Relative_Divergence:** -7.69 -  This suggests a short-term decline in relative strength compared to the S&P 500.
* **Expected Return:** 5.77% -  This represents the potential maximum 5-year return on investment.

**4. Recent Earnings and Outlook:**

**Earnings Summary:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report showed an EPS of 13.25, exceeding analyst expectations.  Revenue also came in above forecasts.  

**5. Comprehensive Analysis:**

REGEN has consistently outperformed the market over the long term, with its recent earnings report demonstrating strong financial performance. However, the current price is below key moving averages and technical indicators suggest potential downward pressure.  

**6. Conclusion:**

While REGEN's long-term prospects remain positive,  the recent price action and technical indicators suggest a cautious approach.  Investors may want to consider waiting for a more favorable entry point before taking a position.  It is important to monitor future earnings reports and news releases for further insights into the company's performance and growth potential.
